AU2005299482A1 - Methods for lowering HIF-1 mediated gene expression - Google Patents

Methods for lowering HIF-1 mediated gene expression Download PDF

Info

Publication number
AU2005299482A1
AU2005299482A1 AU2005299482A AU2005299482A AU2005299482A1 AU 2005299482 A1 AU2005299482 A1 AU 2005299482A1 AU 2005299482 A AU2005299482 A AU 2005299482A AU 2005299482 A AU2005299482 A AU 2005299482A AU 2005299482 A1 AU2005299482 A1 AU 2005299482A1
Authority
AU
Australia
Prior art keywords
hif
cancer
agents
cells
ascorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005299482A
Other languages
English (en)
Inventor
Huasheng Lu
Ajay Verma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of AU2005299482A1 publication Critical patent/AU2005299482A1/en
Assigned to THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. reassignment THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: HENRY M. JACKSON FOUNDATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2005299482A 2004-10-25 2005-10-25 Methods for lowering HIF-1 mediated gene expression Abandoned AU2005299482A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62109104P 2004-10-25 2004-10-25
US60/621,091 2004-10-25
PCT/US2005/038317 WO2006047485A2 (en) 2004-10-25 2005-10-25 Methods for lowering hif-1 mediated gene expression

Publications (1)

Publication Number Publication Date
AU2005299482A1 true AU2005299482A1 (en) 2006-05-04

Family

ID=36228364

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005299482A Abandoned AU2005299482A1 (en) 2004-10-25 2005-10-25 Methods for lowering HIF-1 mediated gene expression

Country Status (6)

Country Link
US (1) US20080045463A1 (enExample)
EP (1) EP1814570A2 (enExample)
JP (1) JP2008517943A (enExample)
AU (1) AU2005299482A1 (enExample)
CA (1) CA2585268A1 (enExample)
WO (1) WO2006047485A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010024908A1 (en) * 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis
WO2012082765A2 (en) * 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
WO2012135397A2 (en) * 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
EP3113766B1 (en) * 2014-03-05 2021-04-07 Evan C. Unger Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
JP7160683B2 (ja) * 2016-04-29 2022-10-25 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 術後癒着の予防及び治療のための方法及び組成物
JP7280470B2 (ja) * 2019-11-29 2023-05-24 慶應義塾 特定アミノ酸またはアミノ酸様物質による低酸素応答制御
CA3218944A1 (en) * 2021-05-16 2022-11-24 Slavica TUDZAROVA-TRAJKOVSKA Methods and compositions for treating cardiovascular disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US6566088B1 (en) * 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules

Also Published As

Publication number Publication date
WO2006047485A3 (en) 2008-03-06
WO2006047485A8 (en) 2007-06-14
EP1814570A2 (en) 2007-08-08
US20080045463A1 (en) 2008-02-21
CA2585268A1 (en) 2006-05-04
JP2008517943A (ja) 2008-05-29
WO2006047485A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AU2017248477B2 (en) Aromatic-cationic peptides and methods for using same
US10925925B2 (en) Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors
US10987345B2 (en) Method for assessing the efficacy of IMiDs and composition or combination for use in treating IMiD sensitive diseases
Gu et al. Curcumin analogue AI-44 alleviates MSU-induced gouty arthritis in mice via inhibiting cathepsin B-mediated NLRP3 inflammasome activation
Deng et al. GPA peptide enhances Nur77 expression in intestinal epithelial cells to exert a protective effect against DSS‐induced colitis
WO2013152038A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
CN102137680A (zh) 用apoe肽治疗癌症的方法
EP2413968B1 (en) Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses
JP2023139018A (ja) 遺伝性シスタチンｃアミロイド血管症（ｈｃｃａａ）および異常なアミロイド沈着を伴う他の神経変性障害の治療のための組成物および方法
US20080045463A1 (en) Methods For Lowering Hif-1 Mediated Gene Expression
WO2012118599A1 (en) C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
WO2025167587A1 (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
CN113209303A (zh) Wwp1通过溶酶体途径降解癌蛋白muc1抑制肿瘤及其应用
Rossi et al. The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy
US7122336B2 (en) Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
Jia et al. USP25-mediated talin-1 stabilization in platelets: a novel mechanism of hyperreactivity and thrombosis risk during aging
US20240382561A1 (en) Glucoregulatory compound, composition and uses thereof
JP2008230977A (ja) ニチジンを成分とする抗癌剤、および該抗癌剤の感受性増強剤
Shi et al. Kynurenine analog 3-HAA is a ligand for transcription factor YY1
Huang et al. Disrupting the physical interaction between serotonin transporter and soluble guanylate cyclase produces a fast–acting antidepressant activity
AU2016220024B2 (en) MCJ agonists and uses therefor
US20120245078A1 (en) Means and methods for treating ischemic conditions
Dagher et al. Articles in PresS. Am J Physiol Renal Physiol (November 2, 2011). doi: 10.1152/ajprenal. 00317.2011
Rai Effect of Lipotoxicity on ER Stress, Autophagy and Apoptosis in Skeletal Muscle and Regulation by Adiponectin

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAME FROM VERMAN, AJA TO VERMAN, AJAY

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS FOR LOWERING HIF-1 MEDIATED GENE EXPRESSION

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period